<p>旧金山，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Structure Therapeutics Inc.（纳斯达克：GPCR），一家临床阶段的全球生物制药公司，专注于开发用于代谢疾病的新型口服小分子治疗药物，特别是肥胖症，今天宣布其增量承销公开发行的定价，发行 8,461,538 份美国存托股票（ADS），每份代表三股普通股，公开发行价格为每份 ADS 65.00 美元，并预先融资的认股权证以每份 64.9999 美元的价格购买 1,538,462 份 ADS。所有证券均由 Structure Therapeutics 出售。</p>
<p>预计 Structure Therapeutics 从此次发行中获得的总收益约为 6.5 亿美元，未扣除承销折扣和佣金及发行费用。此外，Structure Therapeutics 已授予承销商一个 30 天的选择权，以公开发行价格购买最多 1,500,000 份额外的 ADS，扣除承销折扣和佣金。此次发行预计将于 2025 年 12 月 11 日完成，前提是满足惯例的交割条件。</p>
<p>Jefferies、Leerink Partners、Goldman Sachs &amp; Co. LLC、Morgan Stanley、Guggenheim Securities 和 BMO Capital Markets 担任此次发行的联合账簿管理人。LifeSci Capital 和 Citizens Capital Markets 担任此次发行的共同管理人。</p>
<p>此次发行是根据于 2025 年 8 月 6 日向证券交易委员会（SEC）提交的自动货架注册声明（S-3 表格）进行的，包括基础招股说明书，该注册声明在提交时即生效。与此次发行相关的初步招股说明书补充及附带招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上免费获取。与此次发行相关的最终招股说明书补充及附带招股说明书将提交给 SEC，并将在 SEC 网站 www.sec.gov 上免费提供。与此次发行相关的最终招股说明书的副本可在可用时从以下地址获取：Jefferies LLC，注意：股权承销招股说明书部，520 Madison Avenue, New York, NY 10022，电话（877）821-7388，或通过电子邮件联系 Prospectus_Department@Jefferies.com；Leerink Partners LLC，承销部，53 State Street, 40th Floor, Boston, MA 02109，电话（800）808-7525 ext. 6105，或通过电子邮件联系 syndicate@leerink.com；Goldman Sachs &amp; Co. LLC，注意：招股说明书部，200 West Street, New York, NY 10282，电话（866）471-2526，或通过电子邮件联系 prospectus-ny@ny.email.gs.com；Morgan Stanley &amp; Co. LLC，注意：招股说明书部，180 Varick Street, 2nd Floor, New York, NY 10014，电话（866）718-1649，或通过电子邮件联系 prospectus@morganstanley.com；Guggenheim Securities, LLC，注意：股权承销部，330 Madison Avenue, 8th Floor, New York, NY 10017，电话（212）518-9544，或通过电子邮件联系 GSEquityProspectusDelivery@guggenheimpartners.com；以及 BMO Capital Markets Corp.，注意：股权承销部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通过电子邮件联系 bmoprospectus@bmo.com。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内出售这些证券的要约、征求或销售，除非在任何此类州或司法管辖区的证券法下注册或合格之前。</p>
<p><strong>关于 Structure Therapeutics</strong></p>
<p>Structure Therapeutics 是一家以科学为驱动的临床阶段生物制药公司，专注于发现和开发创新的口服小分子治疗药物，以应对具有重大未满足医疗需求的慢性代谢疾病。利用其下一代基于结构的药物发现平台，公司建立了一个强大的 GPCR 靶向管线，拥有多个完全拥有的专有临床阶段口服小分子化合物，旨在超越传统生物制剂和肽类疗法的可扩展性限制，使更多患者能够获得治疗。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》“安全港” 条款所定义的 “前瞻性声明”。除历史事实声明外的所有声明均可视为前瞻性声明，包括但不限于有关预期发行时间和完成情况以及预期发行总收益的声明。此外，当在本新闻稿中使用 “可能”、“可以”、“应该”、“预期”、“相信”、“估计”、“期待”、“打算”、“计划”、“预测” 等类似表达及其变体时，可能与公司相关的内容也可能被视为前瞻性声明。前瞻性声明既不是历史事实，也不是对未来表现的保证。尽管公司相信这些前瞻性声明中反映的预期是合理的，但公司无法保证这些预期将被证明是正确的。读者需注意，实际结果可能与公司前瞻性声明中表达或暗示的结果存在重大差异，这些差异可能源于多种风险和不确定性，包括但不限于市场风险和不确定性、证券发行的惯常成交条件的满足以及公司在向美国证券交易委员会（SEC）提交的文件中描述的其他风险和不确定性，包括公司最新的 10-Q 季度报告和公司可能不时向 SEC 提交的未来报告。本新闻稿中包含的所有前瞻性声明仅在作出声明的日期有效，并基于管理层在该日期的假设和估计。除法律要求外，公司没有义务更新这些声明，以反映作出声明后发生的事件或存在的情况。</p>
<p><strong>投资者：</strong></p>
<p>Danielle Keatley</p>
<p>Structure Therapeutics Inc.</p>
<p>ir@structuretx.com</p>
<p><strong>媒体：</strong></p>
<p>Dan Budwick</p>
<p>1AB</p>
<p>Dan@1abmedia.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNNQ00zTXpFMU1EYzFJekl5TkRZd016Zz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNNQ00zTXpFMU1EYzFJekl5TkRZd016Zz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png"/></p>

GPCR

<p>Structure Therapeutics Inc. 宣布其增大至 6.5 亿美元的 ADS 公开发行定价。此次发行包括 8,461,538 份 ADS，每份价格为 65.00 美元，以及 1,538,462 份预先融资的认股权证，每份价格为 64.9999 美元。此次发行预计将于 2025 年 12 月 11 日完成，Jefferies、Leerink Partners、Goldman Sachs、Morgan Stanley、Guggenheim Securities 和 BMO Capital Markets 将作为联合账簿管理人</p>

<p>SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics.</p>
<div class="lb-trans"><p>旧金山，2025 年 12 月 09 日（GLOBE NEWSWIRE）-- Structure Therapeutics Inc.（纳斯达克：GPCR），一家临床阶段的全球生物制药公司，专注于开发用于代谢疾病的新型口服小分子治疗药物，特别是肥胖症，今天宣布其增量承销公开发行的定价，发行 8,461,538 份美国存托股票（ADS），每份代表三股普通股，公开发行价格为每份 ADS 65.00 美元，并预先融资的认股权证以每份 64.9999 美元的价格购买 1,538,462 份 ADS。所有证券均由 Structure Therapeutics 出售。</p>
</div><p>The gross proceeds to Structure Therapeutics from the offering are expected to be approximately $650 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>预计 Structure Therapeutics 从此次发行中获得的总收益约为 6.5 亿美元，未扣除承销折扣和佣金及发行费用。此外，Structure Therapeutics 已授予承销商一个 30 天的选择权，以公开发行价格购买最多 1,500,000 份额外的 ADS，扣除承销折扣和佣金。此次发行预计将于 2025 年 12 月 11 日完成，前提是满足惯例的交割条件。</p>
</div><p>Jefferies, Leerink Partners, Goldman Sachs &amp; Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital and Citizens Capital Markets are acting as co-managers for the offering.</p>
<div class="lb-trans"><p>Jefferies、Leerink Partners、Goldman Sachs &amp; Co. LLC、Morgan Stanley、Guggenheim Securities 和 BMO Capital Markets 担任此次发行的联合账簿管理人。LifeSci Capital 和 Citizens Capital Markets 担任此次发行的共同管理人。</p>
</div><p>The offering is being made pursuant to an automatic shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (SEC) on August 6, 2025 and became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available for free on the SEC’s website located at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com.</p>
<div class="lb-trans"><p>此次发行是根据于 2025 年 8 月 6 日向证券交易委员会（SEC）提交的自动货架注册声明（S-3 表格）进行的，包括基础招股说明书，该注册声明在提交时即生效。与此次发行相关的初步招股说明书补充及附带招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上免费获取。与此次发行相关的最终招股说明书补充及附带招股说明书将提交给 SEC，并将在 SEC 网站 www.sec.gov 上免费提供。与此次发行相关的最终招股说明书的副本可在可用时从以下地址获取：Jefferies LLC，注意：股权承销招股说明书部，520 Madison Avenue, New York, NY 10022，电话（877）821-7388，或通过电子邮件联系 Prospectus_Department@Jefferies.com；Leerink Partners LLC，承销部，53 State Street, 40th Floor, Boston, MA 02109，电话（800）808-7525 ext. 6105，或通过电子邮件联系 syndicate@leerink.com；Goldman Sachs &amp; Co. LLC，注意：招股说明书部，200 West Street, New York, NY 10282，电话（866）471-2526，或通过电子邮件联系 prospectus-ny@ny.email.gs.com；Morgan Stanley &amp; Co. LLC，注意：招股说明书部，180 Varick Street, 2nd Floor, New York, NY 10014，电话（866）718-1649，或通过电子邮件联系 prospectus@morganstanley.com；Guggenheim Securities, LLC，注意：股权承销部，330 Madison Avenue, 8th Floor, New York, NY 10017，电话（212）518-9544，或通过电子邮件联系 GSEquityProspectusDelivery@guggenheimpartners.com；以及 BMO Capital Markets Corp.，注意：股权承销部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通过电子邮件联系 bmoprospectus@bmo.com。</p>
</div><p>This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不构成在任何州或司法管辖区内出售这些证券的要约、征求或销售，除非在任何此类州或司法管辖区的证券法下注册或合格之前。</p>
</div><p><strong>About Structure Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Structure Therapeutics</strong></p>
</div><p>Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.</p>
<div class="lb-trans"><p>Structure Therapeutics 是一家以科学为驱动的临床阶段生物制药公司，专注于发现和开发创新的口服小分子治疗药物，以应对具有重大未满足医疗需求的慢性代谢疾病。利用其下一代基于结构的药物发现平台，公司建立了一个强大的 GPCR 靶向管线，拥有多个完全拥有的专有临床阶段口服小分子化合物，旨在超越传统生物制剂和肽类疗法的可扩展性限制，使更多患者能够获得治疗。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including without limitation, statements concerning the expected timing and completion of the offering and the expected gross proceeds from the offering. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, market risks and uncertainties, the satisfaction of customary closing conditions for an offering of securities and other risk and uncertainties described in the Company’s filings with the SEC, including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》“安全港” 条款所定义的 “前瞻性声明”。除历史事实声明外的所有声明均可视为前瞻性声明，包括但不限于有关预期发行时间和完成情况以及预期发行总收益的声明。此外，当在本新闻稿中使用 “可能”、“可以”、“应该”、“预期”、“相信”、“估计”、“期待”、“打算”、“计划”、“预测” 等类似表达及其变体时，可能与公司相关的内容也可能被视为前瞻性声明。前瞻性声明既不是历史事实，也不是对未来表现的保证。尽管公司相信这些前瞻性声明中反映的预期是合理的，但公司无法保证这些预期将被证明是正确的。读者需注意，实际结果可能与公司前瞻性声明中表达或暗示的结果存在重大差异，这些差异可能源于多种风险和不确定性，包括但不限于市场风险和不确定性、证券发行的惯常成交条件的满足以及公司在向美国证券交易委员会（SEC）提交的文件中描述的其他风险和不确定性，包括公司最新的 10-Q 季度报告和公司可能不时向 SEC 提交的未来报告。本新闻稿中包含的所有前瞻性声明仅在作出声明的日期有效，并基于管理层在该日期的假设和估计。除法律要求外，公司没有义务更新这些声明，以反映作出声明后发生的事件或存在的情况。</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投资者：</strong></p>
</div><p>Danielle Keatley</p>
<div class="lb-trans"><p>Danielle Keatley</p>
</div><p>Structure Therapeutics Inc.</p>
<div class="lb-trans"><p>Structure Therapeutics Inc.</p>
</div><p>ir@structuretx.com</p>
<div class="lb-trans"><p>ir@structuretx.com</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Dan Budwick</p>
<div class="lb-trans"><p>Dan Budwick</p>
</div><p>1AB</p>
<div class="lb-trans"><p>1AB</p>
</div><p>Dan@1abmedia.com</p>
<div class="lb-trans"><p>Dan@1abmedia.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNNQ00zTXpFMU1EYzFJekl5TkRZd016Zz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg3MCM3MzE1MDc1IzIyNDYwMzg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MzcxOWJmNGMtMjQ2Yy00ZTQwLWIxODEtM2FlZGY2YWE5NDA0LTEyNTc1OTEtMjAyNS0xMi0xMC1lbg==/tiny/Structure-Therapeutics-Inc-.png"/></p>

Structure Therapeutics 宣布定价扩大至 6.5 亿美元的美国存托股票和预先资助认股权证的公开发行 | GPCR 股票新闻